Dr. Ted Ling, MD, MS

Dr. Ling practices at Radiant Oncology Medical Group in Apple Valley, California.

Dr. Ling's NPI, 1902121544, was assigned on April 6, 2010. Dr. Ling graduated from Saint Louis University School Of Medicine in 2010. Dr. Ling holds California license A117954.

Dr. Ling's primary practice is Radiant Oncology Medical Group, at 18564 Us-18, Apple Valley, CA 92307 in San Bernardino County. The practice phone is (760) 202-3946.

Dr. Ling's primary practice is Radiant Oncology Medical Group in Apple Valley, California. Dr. Ling is also affiliated with Eisenhower Health. The medical group on file is Vicura Oncology. Dmand AI also links Dr. Ling to 2 more hospitals, 4 medical groups, 3 group practices and clinics and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ling practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Ling's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Ling is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Ling's licenses on file in 4 states: California, Michigan, Ohio and Arizona.

Dmand AI lists brain cancer radiation, brain tumor radiation, breast cancer radiation, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Ling treats.

CMS data shows 1,498 Medicare services from Dr. Ling across 16 procedure codes in 2024, for 81 Medicare patients. Medicare paid $293,811 for them.

CMS counts 81 Medicare patients who saw Dr. Ling in 2024. The largest group is 65 to 74, with 34 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ling's median patient age at 74, with 42% women.

In 2024, Dr. Ling wrote 197 Medicare Part D claims for 95 patients. 83% of them were for generic drugs. CMS names the drug for 91 of them, across 5 drugs with 11 or more claims each, at $1,122 in total drug cost. In 2023, CMS named 144 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Ling for performance year 2024, reported as part of a group. Dr. Ling accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 13 papers to Dr. Ling, published from 2014 to 2015. 2015 was the busiest year, with 2. Dr. Ling has published most often in J Gastrointest Oncol. Dr. Ling's most frequent co-authors are Gary Y. Yang, MD, Jerry D. Slater, MD and David Alan Bush, MD.

CMS Open Payments shows 60 general payments to Dr. Ling from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Myriad Genetic Laboratories, Inc. paid the most, $359.

Dmand AI lists 8 awards for Dr. Ling, most recently American Brachytherapy Society HDR Scholarship in 2015. Dr. Ling serves on Journal of Proton Therapy.

Dr. Ling graduated from Saint Louis University School Of Medicine in 2010. Dr. Ling is a member of ABS, AMA, ASTRO, ASCO, Particle Therapy Co-Operative Group and RSNA.

Dr. Ling is in network with 16 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.